TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05848193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyHeadHealth online application
Description: MyHeadHealth is an online application to be accessed through the patients smartphone. The goal of MyHeadHealth is to improve treatment compliance by providing patients with free and convenient access to resources and activities that align with their treatment plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive Standard of Care from our concussion clinic as necessary as per the consultation with the physician
Study: NCT06462222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab, pemetrexed
Description: Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
Study: NCT06576089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported, women-centred and aphasia-friendly recruitment and enrollment process (ORDER)
Description: Participants randomized into ORDER will be approached by the Site Coordinator for interest in the host trial. The Coordinator will introduce the trial and share a brief, women-centred, aphasia-friendly, close-captioned video that further describes the trial procedures and an accompanying leaflet.~ORDER recruitment materials will be saved to a mobile tablet. The Coordinator will watch the video together with the potential participant, engage in discussion about the host trial and answer any questions they may have. The Coordinator will offer to leave the tablet with the potential participant, along with printed copies of the leaflet and participant information letter. The Coordinator will encourage them to share these materials with their family members, friends or member of their healthcare team who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional recruitment and enrollment processes (TRAD)
Description: Participants randomized into the traditional recruitment process (TRAD) will be approached by the Site Coordinator for interest in the CAMAROS trial and presented with the standard participant information letter and full informed consent form. The information letter and consent form will be left with the potential participant to view again; the Coordinator will encourage them to share these materials with their family members or friends who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial.
Study: NCT05220046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
Study: NCT05478499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05945147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Study: NCT04289571

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VR Mobility Tool
Description: Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
Study: NCT05337514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement
Description: EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Engagement
Description: Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
Study: NCT05025241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Study: NCT05407675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986408
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Specified dose on specified days
Study: NCT05410665

Intervention type: PROCEDURE
Intervention: Standard treatments for sepsis
Description: Standard treatments for others
Study: NCT05976867

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Teachers (PAT) as usual
Description: Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) + Smart Parents
Description: Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (\~60 min). Parents return to PAT as usual following this session.
Study: NCT05293743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot abduction bracing for clubfoot with novel Dynamic Bar
Description: After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Dynamic Bar.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot abduction bracing for clubfoot with Standard Bar
Description: After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Standard Bar.
Study: NCT04466956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality headset worn with short relaxing video played during MVA procedure
Study: NCT05974293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
Study: NCT04711824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: SRS 1-5 fractions will be given per institutional standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physicians Choice systemic chemotherapy
Description: Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
Study: NCT06083883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 TCR/IL-15 NK
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study: NCT05047237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-Led Optimization Intervention
Description: Educational information mailed to participants and up to three pharmacist visits.
Study: NCT05575128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication optimzation
Description: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Care as usual, with written resources provided
Study: NCT05192954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSureTM vessel sealing device
Description: Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
Study: NCT06206421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT06083220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Start - School Readiness Program
Description: Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
Study: NCT05088980

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VOLBELLA with Lidocaine
Description: Facial Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLBELLA with Lidocaine
Description: Facial Injection
Study: NCT05394428

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01451450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 liquid for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 liquid for subcutaneous injection.
Study: NCT04624750

Intervention type: DRUG
Group type: OTHER
Intervention: Mexiletine
Description: Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study.
Study: NCT05633095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuclare
Description: It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
Study: NCT05476276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA specific
Description: ISA specific interventions will be listed in their protocols.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISA specific
Description: ISA specific interventions will be listed in their protocols.
Study: NCT01451450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 liquid for subcutaneous injection.
Study: NCT05949931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent penpulimab and AVD
Description: Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
Study: NCT05949931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential penpulimab and AVD
Description: Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
Study: NCT01451450

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid for subcutaneous injection.
Study: NCT05214599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Gel
Description: Twice daily regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Gel
Description: Twice daily regimen
Study: NCT01451450

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid for subcutaneous injection.
Study: NCT06290362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Theory-based group consultation
Description: Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events.
Study: NCT04855734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily CEntered (FACE) pACP Intervention
Description: The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach \[Sessions 1 \& 2\] and Respecting Choices \[Session 3\].
Study: NCT05214599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Gel
Description: Twice daily regimen
Study: NCT05965622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)
Description: Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
Study: NCT06568978

Intervention type: OTHER
Intervention: Assessments of respiratory parameters
Description: respiratory muscle strength, respiratory function test

Intervention type: OTHER
Intervention: Assessments of respiratory parameters
Description: respiratory muscle strength, respiratory function test
Study: NCT06274853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules